Serum hydroxybutyrate dehydrogenase and COVID-19 severity and mortality: a systematic review and meta-analysis with meta-regression

Zinellu, Angelo; Paliogiannis, Panagiotis; Carru, Ciriaco; Mangoni, Arduino A.

doi:10.1007/s10238-021-00777-x

Cited by 12 publications

(11 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the survival analysis of this study, it was confirmed that the elevated α-HBDH levels, NLR, WBC, liver metastasis, and age were the risk factors affecting OS, and the association was positive between α-HBDH and the increased risk of OS (HR 1.892, 95%Cl 1.129-3.170, P = 0.015). Studies have shown that elevated α-HBDH in some acute heart and lung diseases suggests poor survival [8,32]. As in other diseases, an increase in this index predicted poor overall survival in LC patients.…”

Section: Table 1 Comparison Of Clinical Characteristics and Laborator...mentioning

confidence: 99%

Prognostic value of serum α-HBDH levels in patients with lung cancer

Zhang¹,

Wang

Chen

2023

World J Surg Onc

View full text Add to dashboard Cite

Background The purpose of our study is to investigate the expression level and prognostic value of serum α-hydroxybutyrate dehydrogenase (α-HBDH) in lung cancer (LC) patients. Method LC patients treated in the Department of Oncology, Shaanxi Provincial Cancer Hospital from January 2014 to December 2016 were included in this study, all of whom underwent serological detection of α-HBDH prior to admission, and were enrolled in follow-up 5-year survival. Comparing the differences between high group and normal groups based on α-HBDH and LDH expression via clinicopathological parameters and laboratory data. Univariate and multivariate regression and overall survival (OS) were analyzed to explore whether elevated α-HBDH was an independent risk factor for LC, compared to LDH. Results Multivariate regression analysis showed that age (P = 0.018), liver metastasis (P = 0.011), α-HBDH (P = 0.015), and neutrophil-to-lymphocyte ratio (NLR) (P = 0.031) were independent prognostic factors affecting OS in LC patients. The overall diagnostic efficacy of α-HBDH (AUC = 0.887) was higher than that of LDH (AUC = 0.709) in the ROC curve. The sensitivity was significantly higher of α-HBDH (sensitivity: 76.06%, specificity: 94.87%) compared with LDH (sensitivity: 49.30%, specificity: 94.87%). The median of OS was more significant in the high-α-HBDH group (6.4 months) than in the normal-α-HBDH group (12.7 months) (P = 0.023). The median of OS was significant in the high-LDH (> 245 U/L) group at 5.8 months and 12.0 months in the normal-LDH (≤ 245 U/L) group (P = 0.068). Conclusions Elevated expression of α-HBDH may indicate a poor prognosis of LC patients. It has a higher sensitivity than LDH and can be used as a potential early biomarker and an independent risk factor predicting the prognosis of LC survival.

show abstract

Section: Table 1 Comparison Of Clinical Characteristics and Laborator...mentioning

confidence: 99%

Prognostic value of serum α-HBDH levels in patients with lung cancer

Zhang¹,

Wang

Chen

2023

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…It was also reported that increased serum concentrations of hydroxybutyrate dehydrogenase (HBDH) were associated with COVID-19 severity and mortality, and suggested that this combined marker of myocardial and renal injury could also be used for risk stratification in COVID-19 ( Zinellu et al., 2021a ).…”

Section: Biomarkers Of Injury Of Organ Systems In Covid19mentioning

confidence: 99%

COVID19 biomarkers: What did we learn from systematic reviews?

Semiz

2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID19) pandemic continues to represent a substantial public health concern. It can rapidly progress to severe disease, with poor prognosis and a high mortality risk. An early diagnosis and specific prognostic tools can help healthcare providers to start interventions promptly, understand the likely prognosis and to identify and treat timely individuals likely to develop severe disease with enhanced mortality risk. Here we focused on an impressive set of systematic reviews and meta-analyses that were performed since the start of the COVID19 pandemic and summarized their results related to the levels of hematologic, inflammatory, immunologic biomarkers as well as markers of cardiac, respiratory, hepatic, gastrointestinal and renal systems and their association with the disease progression, severity and mortality. The evidence outlines the significance of specific biomarkers, including inflammatory and immunological parameters (C-reactive protein, procalcitonin, interleukin-6), hematological (lymphocytes count, neutrophil-to-lymphocyte ratio, D-dimer, ferritin, red blood cell distribution width), cardiac (troponin, CK-MB, myoglobin), liver (AST, ALT, total bilirubin, albumin) and lung injury (Krebs von den Lungen-6) that can be used as prognostic biomarkers to aid the identification of high-risk patients and the prediction of serious outcomes, including mortality, in COVID19. Thus, these parameters should be used as essential tools for an early risk stratification and adequate intervention in improving disease outcomes in COVID19 patients.

show abstract

“…Acute hepatitis and heart and kidney injury may cause the increase of HBDH. 27 After the injection of neutrobots, HBDH in the PTX free neutrobots group and the PTX loaded neutrobots group increased slightly (Fig. 3C).…”

Section: Effects Of Neutrobots Toward Liver In Vivomentioning

confidence: 89%